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S U M M A R Y
Objective: To determine factors associated with the diagnosis of tuberculous uveitis and the response to
anti-tuberculous treatment (ATT).
Methods: A retrospective case study was performed at the University Medical Centre Utrecht between
October 2007 and December 2009. Patients with possible tuberculous uveitis (TBU) were selected from
all patients with an unexplained uveitis. Demographics, ethnicity, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), tuberculin skin test (TST), QuantiFERON (QFT) test, and ocular ﬁndings were
evaluated. An interdisciplinary panel discussed if there was a presumed TBU and decided to start
treatment. When there was a decrease in intraocular cell count and/or improvement in visual acuity after
ATT, the conﬁrmation of presumed TBU was made.
Results: Of 585 patients with unexplained uveitis, 66 (11.3%) fulﬁlled the deﬁnition of possible TBU. Ten
(15.4%) patients were regarded as having presumed TBU and received ATT. All of them had latent
tuberculosis (LTB). The ocular situation improved in seven patients (70%). A history of TB contact,
abnormalities on chest radiology, and extraocular manifestations of TB were associated with a good
response to ATT in the case of presumed tuberculous uveitis.
Conclusions: Tuberculous uveitis remains difﬁcult to diagnose. No clearly correlating factors that
predicted the response to ATT, including ocular parameters, could be identiﬁed.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculous uveitis (TBU) is a subject of renewed interest.
Following the decrease in the incidence of tuberculosis (TB) from
around the 1960s in Western countries, this disease was less
frequently seen as a cause of uveitis. Despite this, TB remains a
major health problem in most countries of the world, especially in
developing countries. In The Netherlands, as in other developed
countries, the incidence of this disease has risen slightly in recent
years,1,2 emphasizing the relevance of the question of whether TB
might be the cause of an otherwise unexplained uveitis.
The incidence of TBU varies signiﬁcantly between studies. The
reported incidence of ocular involvement during TB infection
ranges from 1.4% in a sanatorium study by Donahue in 1967 to
16% in a high-endemic population in Saudi Arabia and 18% in
patients with culture-proven TB in Spain, most without ocular
complaints.3–5 An incidence of 2.8% was reported among HIV-
positive TB patients in Africa, however the presence of
intermediate  or posterior uveitis was not investigated.6 In a* Corresponding author. Tel.: +31882506029.
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compared to 6–7% of all uveitis causes in countries with a low
endemic index of TB.7,8
The diagnosis of tuberculous uveitis is difﬁcult since microbio-
logical techniques (culture and PCR) on ocular ﬂuids are often
negative.9 This might be due to a low number of microorganisms or
the hosting of the bacillus primarily in the retinal pigment
epithelium. It has been suggested that the inﬂammation could be
due to a hypersensitivity reaction to a tubercle bacillus, rather than
due to the microorganism itself.10
Ocular ﬁndings are not speciﬁc. Posterior uveitis and panuveitis
are the most common clinical presentations, but every part of the
eye can be involved. Serpiginous-like choroiditis has been
associated with TB. Mackensen et al. found QuantiFERON test
(QFT) positivity in 52% of patients with these ocular ﬁndings,
compared to 13% in subjects with other forms of uveitis.11 In a
biopsy-proven population of TB and sarcoidosis with uveitis in
South India, a positive tuberculin skin test (TST), Schirmer test
>10 mm, and retinal vasculitis with areas of multiple, pigmented
chorioretinal atrophy along blood vessels, were signiﬁcant clinical
variables in distinguishing TBU from uveitis due to sarcoidosis.12
After reviewing the current literature, Yeh et al. concluded that the
yield of examination of intraocular ﬂuids for detecting the DNA ofses. Published by Elsevier Ltd. All rights reserved.
Table 1
Deﬁnitions
Deﬁnitions
Latent TB An infection with Mycobacterium tuberculosis as shown by
1) a positive TST, and/or
2) a positive QFT, and/or
3) calciﬁed granulomas on chest radiology,
with no signs of active disease
Possible TBU 1) an unexplained uveitis after thorough diagnostic
workup, and
2) ocular abnormalities compatible with TB, and
3) TST, or QFT, or abnormalities on chest radiology ﬁtting
with TB
Presumed TBU A panel of ophthalmologists and infectiologists decided to
start ATT based on anamnesis, ocular ﬁndings, and
additional investigations
Conﬁrmed TBU Positive response to ATT at the end of follow-up:
1) a decrease in intraocular cell count and no loss or
increase in visual
acuity, or
2) no increase in intraocular cells with an increase in visual
acuity,
all corrected for macular edema and non-treated cataracts
ATT, anti-tuberculous treatment; QFT, QuantiFERON gold test; TB, tuberculosis;
TBU, tuberculous uveitis; TST, tuberculin skin test.
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staged analysis and a multidisciplinary approach with ophthal-
mologists and infectiologists.13
Making the correct diagnosis has important therapeutic
consequences, since tuberculous uveitis should be treated with
tuberculostatic drugs to prevent visual loss instead of immuno-
suppressive drugs only.
In recent years several studies and reviews have been published
in which patients with latent TB and uveitis of unknown origin
after thorough workup were treated with tuberculostatic drugs.14–
17 However, the latent TB only means that there was contact with a
tubercle bacillus in the past, it is not an indicator of active disease.
Therefore, the purpose of this study was to determine more clinical
and diagnostic parameters associated with tuberculous uveitis in a
low endemic setting.
2. Materials and methods
2.1. Study design and setting
A retrospective case study was performed at the University
Medical Centre Utrecht, a tertiary referral center for uveitis. The
study period was from October 2007 to December 2009.
2.2. Patient selection
All patients presenting with an unexplained uveitis to the
Department Ophthalmology are routinely subjected to microbio-
logical diagnostics. Patients were considered eligible if one or more
of the following tests was ordered: (1) a PCR for Mycobacterium
tuberculosis performed on anterior chamber ﬂuid or vitreous ﬂuid,
(2) serological tests (Treponema pallidum particle agglutination
assay, cytomegalovirus, Toxoplasma, rubella, herpes simplex virus,
varicella zoster virus), and (3) a QFT. The serological tests and the
QFT had to be ordered by an ophthalmologist. The data were
extracted from the electronic microbiology database (GLIMS
(MIPS), version 8.4.3). After selection, the medical ﬁles were
screened. All patients who (1) had no uveitis, or (2) were strongly
suspected to have a cause for their uveitis other than TB, or (3) had
a ﬁrst episode of anterior uveitis, were excluded. Normally no
additional investigations are performed in the case of a ﬁrst
presentation with an anterior uveitis since it often concerns a
single episode.
The medical ﬁles of the remaining group of patients were
screened again and all patients who fulﬁlled the criteria for
possible tuberculous uveitis were included (Table 1).
2.3. Data collection
Data were collected concerning demographics, ethnicity, and
possible TB contact. For this purpose countries of origin or
countries visited were grouped into a low, intermediate, or high
endemic TB index, in accordance with the World Health
Organization (WHO) ranking.1
Further data were collected on the use of immunosuppressants,
ocular and tuberculostatic drugs, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), TST, QFT, and chest radiology.
Information was also collected on additive examinations such as
extrathoracic radiology, staining and culture of the sputum, and
examination of suspected lesions elsewhere in the body. TST
results were interpreted in accordance with the current guide-
lines,18 and QFT in accordance with the manufacturer’s guidelines
(QuantiFERON1-TB Gold; Cellestis Ltd, Carnegie, Victoria,
Australia). Indeterminate test results were regarded as ‘no test
has been performed’.Ocular parameters were obtained from the outpatient ﬁles of
the ophthalmology department. Extracted data were fundus
image, ocular surgery, and other ocular morbidities like macular
edema and cataracts. The intraocular cell count and visual acuity
were noted at inclusion, at the start of speciﬁc treatment, after 2
and 6 months of treatment, and at the most recent visit before
closure of data collection.
2.4. Evaluation of the response to treatment
The intraocular cell count was scored using the standardized
grading scheme developed by the Standardization of Uveitis
Nomenclature (SUN) Working Group.19
Visual acuity was determined using the Snellen visual chart. The
treatment response was calculated by comparing ocular parameters
at the time of inclusion to the values at the end of follow-up.
The decision to start empirical treatment with anti-TB
treatment (ATT) was made by a panel of infectious diseases
specialists and ophthalmologists. The standard work-up included a
clinical evaluation by the infectious diseases specialist, laboratory
tests including CRP, ESR, and blood count, a chest X-ray or high-
resolution computed tomography (HRCT) scan, and TST or QFT
examinations. The decision to start ATT was based on history, the
presence of signs of active or latent TB, fundus image, ocular
inﬂammation, and the possibility of alternative explanations or
treatment options. The duration of treatment depended on the
ocular situation after 2–4 months. In the case of no improvement,
the tuberculostatic treatment was discontinued. Treatment regi-
mens were those recommended in the current guidelines.18
Patients not receiving ATT received conventional treatment,
meaning any kind of treatment necessary in the judgment of the
treating ophthalmologist. In these cases the panel judged that the
suspicion of TBU was not strong enough to justify ATT. Both
patients with ATT and conventional treatment received local or
systemic immunosuppressants if necessary, as judged by a
clinician.
2.5. Statistical analysis
Several factors were analyzed for a predictive value on the
outcome ‘tuberculous uveitis’ using the Chi-square for nominal
variables and the Mann–Whitney U-test for ordinal and ratio
Table 2
Baseline patient data (N = 66)
Patient characteristics
Gender, female 41 (62.1%)
Mean age (years)  SD 46.9 (18.8)
Risk factors for TB
TB in the pasta 6 (9.1%)
Origin from or travel to an endemic TB countryb 33/63 (52.4%)
Obvious TB contact 8/57 (12.1%)
Proven or strongly suspected extraocular TB 7/66 (10.6%)
PCR on Mycobacterium positive 1
Culture positive 1
Based on radiology/histology 5
Latent TBc
QuantiFERON and/or TST positive 18/55 (32.7%)
QFT and TST positive 6/20 (30.0%)
BCG vaccination in the past (n = 51) 9/51 (17.6%)
BCG vaccinated and TST positive 4/4 (100%)
BCG vaccinated and QFT positive 8/9 (88.9%)
Investigations
Anamnesis
Anamnestic signs of systemic TB infectiond 3/64 (4.7%)
Radiology
Abnormalities on chest radiology
compatible with TBe,f
15/64 (23.4%)
Laboratory
ESR (n = 49), median (IQR) mm/h 9 (5–18)
CRP mg/L (n = 57), median (IQR) 2 (2–5)
Use of immunosuppression
Immunosuppressive medication in the eye by
the ﬁrst visit
44 (66.7%)
Systemic immunosuppression at or within 3
months before the ﬁrst visit
14 (21.2%)
Ophthalmologic ﬁndings
Unilateral uveitis 13 (19.7%)
Bilateral uveitis 53 (80.3%)
Location of uveitis
Anterior 8 (12.1%)
Intermediate 4 (6.1%)
Posterior 20 (30.3%)
Panuveitis 34 (51.5%)
A.G. Vos et al. / International Journal of Infectious Diseases 17 (2013) e993–e999 e995variables. For all tests, p < 0.05 was considered statistically
signiﬁcant. The statistical analysis was performed using SPSS
version 15.0 (SPSS, Chicago, IL, USA).
Patients with good results on ATT were compared to patients
with no response on ATT and patients with a good response to
other therapies. Patients with no ATT and no response to other
therapies were excluded from the analysis, since it was not
possible to determine if these were real false-negative tuberculous
uveitis cases.
Finally we did a separate analysis for treatment outcome in
patients with latent TB, since this is sometimes used as a single
parameter on which the decision to start ATT is based in the case of
an otherwise unexplained uveitis.
3. Results
3.1. Patients
During the 25-month study period, 585 patients were identi-
ﬁed. After initial screening, 10 patients did not have uveitis; 287
patients had a documented known or strongly suspected cause of
uveitis other than TB. Sixty-six patients (11.3%) fulﬁlled the
deﬁnition of possible TBU and were included. There was a
suspicion of another ocular diagnosis in two of them: one patient
with a diagnosis of Behc¸et’s disease and one with a rubella
infection. One patient had been treated for tuberculous uveitis in
the past. Due to a relapse in ocular inﬂammation she was
considered eligible (Figure 1).
Forty-one of the participants (62.1%) were female (Table 2), and
the mean age was the same in the two sexes. Three of the patients
who had a QFT done (n = 53) had an indeterminate test result.
Twenty-ﬁve patients had a positive QFT and/or TST, of whom
76% had a history of originating from or travelling to an endemic TB
country. Four patients had signs of old TB on radiology, not
supported by a positive TST or QFT. Systemic TB was conﬁrmed or
strongly suspected in seven patients (Table 3). Almost 25% (n = 15)
of the patients had abnormalities on chest radiology suggestive of
TB.
3.2. Ocular ﬁndings
Concerning the ophthalmologic ﬁndings, no cultures (n = 54) or
PCRs (n = 49) on ocular ﬂuid were positive. Only one patient had
had a positive PCR for Mycobacterium on vitreous ﬂuid 15 years
earlier (Table 2). The majority of patients presented with a
panuveitis (Table 2). About 50% of the patients had some degree of
papillitis and/or cystoid macular edema and/or vasculitis. No
choroidal tubercles were reported.n = 585 
n = 284 
n = 10 
No uveïtis 
n = 287  
Known cause of uveïtis 
Exclusion  
n = 66 
n = 222 
Do not meet the definition 
‘possible tuberculous uveïtis’ 
Inclusion 
Figure 1. Flowchart of study inclusion.Of the 66 patients, 11 (16.7%) were deﬁned as presumed TBU
and treated with ATT (Table 3). The other patients received
conventional immunosuppressive treatment. All had latent TB.
These 11 patients included the seven patients with signs of
systemic TB. One of the 11 patients was excluded from the analysis
of the treatment response since ATT was started at the end of the
study period. The median follow-up was 0.63 years (interquartile
range 0.22–2.77 years). Five patients used immunosuppressive
drugs during ATT, mainly corticosteroids. When the 10 patients
treated with ATT were grouped by ‘response’ or ‘no response’, ﬁve
out of seven (71.4%) with a good response to ATT received systemic
corticosteroids during ATT, as compared to zero out of three
patients with no effect on ATT (p = 0.04) (Figure 2).Fundus image
Vasculitis 19 (28.8%)
Occlusive vasculitis 12 (18.2%)
Chorioretinitis 13 (19.7%)
Choroiditis 1 (1.5%)
Vasculitis and chorioretinitis 2 (3.0%)
Retinal detachment 1 (1.5%)
No abnormalities 18 (27.3%)
Papillitisg 34 (51.5%)
Cystoid macular edemag 35 (53,0%)
BCG, bacille Calmette–Gue´rin; CRP, C-reactive protein; ESR, erythrocyte sedimen-
tation rate; IQR, interquartile range; SD, standard deviation; TB, tuberculosis; TST,
tuberculin skin test.
a Proven and adequately treated TB infection in the past.
b Endemic is deﬁned in accordance with the WHO ranking.
c Patients with proven or strongly suspected systemic TB were excluded.
d b signs, any of the following: night sweats, weight loss, fever.
e Chest X-ray or high-resolution computed tomography.
f Abnormalities like (calciﬁed) granulomas and mediastinal lymphadenopathy.
g Developed at any time during follow-up.
Table 3
Patients who received anti-tuberculous treatment
Sex, age
(years)
Country of origin TB contacta Latent TB Systemic TB Chest radiology Ocular ﬁndings ATT regimenb Duration
of therapy
(months)c
Immuno-
suppressantsd
Response
to ATT
Duration of
follow-up
(months)
F, 38 The Netherlands Yes QFT-pos
TST-pos
- X-ray normal Posterior uveitis
with chorioretinitis
HRZE 6 Yes Yes 5.1
M, 48 Turkey No QFT-pos
No TST
BCG-pos
- X-ray normal
HRCT compatible with TB
Panuveitis,
granulomatous
with occlusive
vasculitis
Unknown regimen 6 Yes Yes 12.3
F, 75 Indonesia Yes QFT-pos
TST-neg
- X-ray and HRCT
abnormal; Dx sarcoidosis
Panuveitis with
chorioretinitis
2HRZM 4HR 6 No Yes 2.8
M, 73e The Netherlands No TST-pos PCR on aqueous
humor
positive for
Mycobacterium
X-ray normal Posterior uveitis,
granulomatous with
chorioretinitis
HRZ 9 Yes No 172.5
F, 57 Indonesia Unknown Night sweats
TST-pos
Chest radiology
showed multiple
granulomas
X-ray showed
granulomas,
compatible with
TB in the past
Anterior uveitis,
granulomatous,
no fundal
abnormalities
2HRZEM 4HR 6 No Yes 9.7
F, 41 Vietnam Yes QFT-pos
No TST
BCG-pos
Abdominal TB,
ascites culture
positive for TB
X-ray and HRCT
normal
Posterior uveitis
with chorioretinitis
HRZ 9 Yes No 92.8
F, 66 The Netherlands Yes QFT-pos
TST-pos
Cervical
lymphadenopathy;
histology:
granulomatous
inﬂammation
X-ray and HRCT:
pleural thickening in
the left upper lobe
with bronchiectasis,
compatible with
TB in the past
Panuveitis with
vasculitis
HRZE 9 No No 11.4
M, 22 Curac¸ao Yes Night sweats
QFT-pos
TST-pos
BCG-pos
Abnormalities
on HRCT strongly
suggestive of TB
X-ray normal Posterior uveitis
with occlusive
vasculitis
2HRZM 4HRM 6 Yes Yes 3.0
M, 42 Algeria Yes QFT-pos
No TST
BCG-pos
Calciﬁed granulomas
in liver and spleen
X-ray and HRCT
showed calciﬁed
granulomas in the
liver and spleen;
no pulmonary
abnormalities
Posterior uveitis,
granulomatous with
occlusive vasculitis
2HRZE
4HR
6 Yes Yes 6.4
F, 68 The Netherlands Yes QFT-pos
No TST
Calciﬁed lymph
nodules
in the spleen
X-ray and HRCT
showed calciﬁed
granulomas in the
spleen; no pulmonary
abnormalities
Posterior uveitis
with vasculitis
HRZE 9 Yes Yes 15.4
ATT, anti-tuberculosis therapy; BCG, bacille Calmette–Gue´rin; Dx, differential diagnosis; F, female; HRCT, high-resolution computed tomography; M, male; QFT, QuantiFERON gold test; TB, tuberculosis; TST, tuberculin skin test.
a TB contact in The Netherlands or travel to an endemic TB country, according to the WHO ranking.
b H, isoniazid; R, rifampin; E, ethambutol; Z, pyrazinamide; M, moxiﬂoxacin.
c Intentional duration of therapy.
d Use of any systemic immunosuppressive drug within 3 months before the start of ATT or during ATT.
e This patient had been treated for systemic TBwith a PCR-proven tuberculous uveitis in the past. Since ocular inﬂammation relapsed frequently shewas analyzed again. No other diagnoses were found, so her ocular inﬂammation
was considered to be related to the TB infection in the past.
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Table 4
Conﬁrmed TBU versus no TBU
Conﬁrmed TBU (n = 7) No TBUa (n = 36) p-Value
Patient characteristics
Gender, male 3 (42.9%) 12 (33.3%)
Age, median (IQR) years 56.1 (37.7–67.8) 40.3 (24.2–54.6)
Systemic immunosuppression within 3 months of diagnosis 1 (14.3%) 7 (19.4%) NS
Risk factors for TB
TB in the past 1/7 (14.3) 2/36 (5.6%) NS
Origin from an endemic TB country 4/7 (57.1%) 7/33 (21.2%) 0.05
Origin from or visit to endemic TB country 0.04
Median endemic index 5 (71.4%) 10 (30.3%)
High endemic index 2 (28.6%) 6 (18.2%)
Contact with persons with TB 2 (33.3%) 5 (16.1%)
Latent TB
Latent TB (Mantoux and/or QFT-positive) 7 (100%) 9 (26.5%) 0.000
Mantoux-positive 3/4 (75.0%) 6/17 (35.3%) NS
BCG vaccination in the past 3/6 (50.0%) 4/29 (13.8%) 0.04
QFT-positive 6/6 (100%) 6/29 (20.7%) 0.000
Clinical ﬁndings
Signs of systemic TB infection 2 (28.6%) 0 0.001
Proven or strongly suspected TB infection (n = 7) 4/7 (57.1%) 3/36 (8.3%) 0.001
CRP,b median (IQR) Mean rank 16.8
2.5 (2.0–5.25)
Mean rank 16.4
2.0 (2.0–5.25)
NS
ESR, median (IQR) mm/h Mean rank 20.3
9.0 (3.0–50.0)
Mean rank 18.7
8.0 (5.0–18.0)
NS
Chest radiology
Abnormalities compatible with TBc 6/7 (85.7%) 6/34 (17.6%) 0.000
Treatment with immunosuppressive drugsd 5/7 (71.4%) 20/36 (55.6%) NS
Ocular characteristics
Location of uveitis NS
Anterior 1 (14.3%) 5 (13.9%)
Posterior 4 (57.1%) 10 (27.8%)
Intermediate 0 2 (5.6%)
Panuveitis 2 (28.6%) 19 (52.8%)
Granulomatous uveitis 3 (42.9%) 10 (27.8%) NS
Fundus image
Vasculitis 1 (14.3%) 12 (33.3%)
Occlusive vasculitis 3 (42.9%) 6 (16.7%) NS
Chorioretinitis 2 (28.6%) 6 (16.7%)
Normal fundus 1 (14.3%) 10 (27.8%) NS
Vasculitis and chorioretinitis 0 2 (5.6%)
Vasculitis (including occlusive, with or without chorioretinitis) 4 (57.1%) 20 (55.6%) NS
BCG, bacille Calmette–Gue´rin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; NS, not signiﬁcant; QFT, QuantiFERON gold test; TB,
tuberculosis; TBU, tuberculous uveitis.
a Patients with no response to ATT or with a good response to conventional treatment (3 + 33, n = 65).
b Mann–Whitney U-test.
c Inclusive of old TB.
d Any time during follow-up, all types of systemic immunosuppressive drug.
TST or QFT 
n = 61/65 
Negative 
n = 37 
Positive 
n = 24 
No ATT 
n = 37 
ATT 
n = 0 
Success 
n = 7 
TBs 4/7 
Steroids 5/7  
Failure 
n = 3 
TBs 3/3 
Steroids 0/3  
No ATT n = 14 
TBs: 0/14 
Steroids: 7/14 
ATT n = 10 
TBs: 7/10 
Steroids: 5/10  
Success 
n = 6  
TBs 0 
Steroids 3/6  
Failure 
n = 8 
TBs 0 
Steroids 4/8  
Success 
n = 25 
TBs 0 
Steroids 15/25 
Failure 
n = 12 
TBs 0 
Steroids 7/12  
Figure 2. Course of patients with a positive tuberculin skin test and/or QuantiFERON test (TST: tuberculin skin test; QFT: QuantiFERON test; ATT: anti-tuberculous treatment;
TBs: systemic tuberculosis; steroids: use of any systemic corticosteroids during treatment).
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Of the 10 (15.4%) patients who received ATT, treatment was
successful in seven (70%), who were subsequently regarded as
having conﬁrmed TBU. Of the 55 patients who received conven-
tional treatment, 33 (60%) improved (Table 4). All patients with a
conﬁrmed TBU had a positive QFT or TST. Abnormalities on chest
radiology and systemic TB were more frequently seen in these
patients. No difference was found in the use of either local or
systemic immunosuppressive drugs between the two groups. No
speciﬁc ocular ﬁnding was associated with tuberculous uveitis.
3.4. Course of patients with a positive TST and/or QFT
Of all patients with a positive QFT or TST (n = 24), 14 (58.3%) did
not receive ATT. Of these 14 patients, six patients improved (43%)
with conventional treatment, whereas for eight patients there was
no difference or even a deterioration in the situation (Figure 2). In
this group, no difference in the use of systemic immunosuppres-
sive drugs was found between patients with a good effect and no
effect (50% in both groups).
4. Discussion
Possible TB contact, latent TB, systemic TB, and abnormalities
on chest radiology were associated with a diagnosis of tuberculous
uveitis, whereas ESR, CRP, and ocular ﬁndings were found not to
have any predictive value. However, no clearly correlating factor
for the diagnosis of TBU could be identiﬁed.
These results show that it is difﬁcult to differentiate between
TBU and uveitis of other causes. The clinical presentation is not
speciﬁc. Culture or PCR on ocular ﬂuid is almost always negative.
Other investigations, like TST and/or QFT, do not distinguish
between latent and active TB infection. Even in the case of
histopathologically proven ocular TB, the TST was positive in only
59% and the chest radiograph was normal in 57% of the patients.20
Clinical suspicion is mainly based on anti-inﬂammatory drug-
resistant uveitis, with no evidence of a differential diagnosis, in the
presence of latent TB.
Whether TBU occurs more frequently in latent TB than in active
TB is not clear. Prevalence data are scarce and conﬂicting, reﬂecting
the difﬁcult diagnostic process. Several studies have demonstrated
that the prevalence of latent TB is higher in patients with uveitis of
unknown origin than in healthy individuals.11,21 A recent study in a
tertiary referral center in France suggested a prevalence of 10% of
TBU in idiopathic ocular inﬂammation.16 In 500 patients with
scleritis in the USA, ﬁve patients were diagnosed with TB (1%).22
Our data might reﬂect a prevalence of TBU in unexplained uveitis
of 11% (seven out of 66 patients).
Recently, several authors have struggled with the same
question and have also attempted to identify factors related to
TBU.14,15,16 Ang et al.14 calculated positive and negative predictive
values (PPV and NPV) of latent TB, deﬁned as either a positive QFT
or TST, as a diagnostic tool for tuberculous uveitis. They reported a
PPV of 84.6% and an NPV of 78.9% in a group of patients with both a
positive TST and QFT, analyzed for their response to ATT. We tried
to ﬁnd more predictive factors, since latent TB is one of the
predictive factors but has no causal relationship with uveitis of
unknown origin.
The positive ﬁndings concerning demographics and tubercu-
lous uveitis are in line with known associations with systemic TB,
and are therefore possibly caused by allocation bias. A possible TB
contact and latent TB might have been important factors in
deciding whether or not to start ATT.
Besides the small number of patients, a major drawback of this
study is a lack of standardization. We used a practical baseddeﬁnition of possible tuberculous uveitis to identify all patients
with a suspected tuberculous uveitis during the 26 months of our
study. The disadvantage of such a deﬁnition is that the moment the
suspicion was raised differed greatly. For example, one patient had
had a diagnosis of tuberculous uveitis 15 years earlier, and since
her complaints were still ongoing, with no other explanatory
diagnosis, she was included. Other patients had had complaints for
only a few months. The diagnostic workup was not the same for all
cases. However, the most important investigations, like screening
blood tests and investigation for latent TB by chest radiology, TST,
or QFT, were done in most patients.
The decision to start ATT was not standardized and might have
been inﬂuenced by the experience or personal preference of the
treating ophthalmologist and infectious diseases specialist. The
duration of follow-up varied considerably, so the effect of
treatment should be interpreted with caution.
Another limitation is the lack of a gold standard to diagnose
tuberculous uveitis. Culture and PCR on ocular ﬂuid are almost
always negative. We used, as previously done,14 the effect of ATT
on ocular parameters as the outcome measure. In particular, visual
acuity is a difﬁcult measure since it is inﬂuenced by many factors.
By correcting for macular edema and cataracts, many other
inﬂuencing factors may not be addressed.23 The intraocular cell
count seems to be a more reliable outcome measure, although it
may be inﬂuenced by inter-observer variability and inaccuracy in
reporting.
The ocular situation in seven out of 10 patients receiving ATT
improved. This is in line with the results of Gineys et al.16 and
Sanghvi et al.24, who found that 60% and 70%, respectively, of the
patients receiving ATT for possible TBU improved. An interesting
ﬁnding is the fact that patients treated with ATT and systemic
corticosteroids had a signiﬁcantly better response as compared
to patients treated with ATT and no corticosteroids. This raises
the question of whether ATT or systemic corticosteroids are
responsible for the response rate. Various studies have suggested
treatment with both ATT and systemic corticosteroids to limit
damage to the ocular tissues caused by delayed-type hypersen-
sitivity.10,25 However, in a recent study by Gineys and
associates,16 60% of cases receiving ATT improved without
corticosteroids.
Our study underlines the need for a standardized diagnostic
workup and decision-making with regard to treatment with ATT.
A possible moment of inclusion could be when uveitis of
unknown etiology remains after thorough investigation. These
patients should be questioned about possible TB contact.
Screening blood tests could be omitted, and TST or QFT and
chest radiology should be performed. After collecting this
information and test results, the decision to start ATT can be
standardized. Further research should focus on the additional
value of systemic corticosteroids with ATT, or even treatment
with corticosteroids alone.
Our research highlights the difﬁculties in diagnosing tubercu-
lous uveitis. Due to the low incidence of TB, only a small number of
patients could be included. The diagnostic workup for unexplained
uveitis and the decision on whether to start treatment has not yet
been standardized in our hospital. Developing a protocol for the
diagnostic workup and the decision to start ATT in the case of
unexplained uveitis, would result in more transparent decisions
and veriﬁable results. Adding systemic corticosteroids to ATT
might increase the treatment response.
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